Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.78 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3505316 | 0.94 | PDE10A (0.69) | PDE10AELOVL1HTTMALT1CYP1A2 | |
| SCHEMBL3506103 | 0.88 | PDE10A (0.78) | PDE10AHTTPTGDR2ARALDH1A1 | |
| SCHEMBL3505967 | 0.88 | PDE10A (1.00) | PDE10AHTTPTGDR2ARALDH1A1 | |
| SCHEMBL2501874 | 0.86 | PDE10A (0.71) | PDE10AALDH1A1KDM4EHPGD | |
| SCHEMBL7914942 | 0.85 | PDE10A (0.74) | PDE10AHTTPTGDR2ARALDH1A1 | |
| SCHEMBL3509469 | 0.84 | PDE10A (0.64) | PDE10AELOVL1HTTALDH1A1CYP1A2 | |
| SCHEMBL2472403 | 0.83 | PDE10A (0.70) | PDE10AALDH1A1MALT1CYP1A2CYP3A4 | |
| SCHEMBL2750597 | 0.83 | PDE10A (0.70) | PDE10AALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2499608 | 0.83 | PDE10A (0.75) | PDE10AHTTPTGDR2ARALDH1A1 | |
| SCHEMBL3506423 | 0.83 | PDE10A (0.69) | PDE10AMALT1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187455-B2 | Substituted pyridazines as PDE10A inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-11-17 | — | — | US | claimed |
| EP-2398795-B1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-15 | — | — | EP | claimed |
| EP-2398795-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | claimed |
| WO-2010094762-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | claimed |
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | claimed |
| US-9187455-B2 | Substituted pyridazines as PDE10A inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187455-B2 | Substituted pyridazines as PDE10A inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187455-B2 | Substituted pyridazines as PDE10A inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2398795-B1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-15 | — | — | EP | disclosed |
| EP-2398795-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2010094762-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | PDE3A, PDE10A, PDE5A | PDE10A 2/4885ELOVL1 3029/4885HTT 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.